PART I BUSINESS Overview We are a clinical-stage biopharmaceutical company focused on our Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75% of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination o...
Q2 FY2026 — expected 2026-07-14
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-04-15 | 2024-12-31 | 0001641172-25-004819 | EDGAR | 62K words |
| 2024-04-15 | 2023-12-31 | 0001493152-24-014625 | EDGAR | — |
| 2023-03-31 | 2022-12-31 | 0001493152-23-010284 | EDGAR | — |
| 2022-03-21 | 2021-12-31 | 0001493152-22-007377 | EDGAR | — |
| 2021-03-31 | 2020-12-31 | 0001493152-21-007532 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-14 | 2025-09-30 | 0001493152-25-023539 | EDGAR | 9K words |
| 2025-08-14 | 2025-06-30 | 0001641172-25-024066 | EDGAR | — |
| 2025-05-20 | 2025-03-31 | 0001641172-25-011731 | EDGAR | — |
| 2024-11-14 | 2024-09-30 | 0001493152-24-045938 | EDGAR | — |
| 2024-08-14 | 2024-06-30 | 0001493152-24-032278 | EDGAR | — |
| 2024-05-20 | 2024-03-31 | 0001493152-24-020710 | EDGAR | — |
| 2023-10-19 | 2023-09-30 | 0001493152-23-037702 | EDGAR | — |
| 2023-08-21 | 2023-06-30 | 0001493152-23-029605 | EDGAR | — |
| 2023-05-22 | 2023-03-31 | 0001493152-23-018539 | EDGAR | — |
| 2022-11-14 | 2022-09-30 | 0001493152-22-032057 | EDGAR | — |
| 2022-08-15 | 2022-06-30 | 0001493152-22-022956 | EDGAR | — |
| 2022-05-20 | 2022-03-31 | 0001493152-22-014639 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2025-12-18 | 0001493152-25-028361 | EDGAR | 1K words |
| 2025-07-24 | 0001641172-25-020843 | EDGAR | — |
| 2024-12-19 | 0001493152-24-050777 | EDGAR | — |
| 2024-06-17 | 0001493152-24-024035 | EDGAR | — |
| 2024-02-20 | 0001493152-24-007223 | EDGAR | — |
| 2024-02-14 | 0001493152-24-006664 | EDGAR | — |
| 2023-12-15 | 0001493152-23-045048 | EDGAR | — |
| 2023-04-13 | 0001493152-23-012053 | EDGAR | — |
| 2023-03-13 | 0001493152-23-007316 | EDGAR | — |
| 2022-12-09 | 0001493152-22-035047 | EDGAR | — |
68 total filings indexed. 41 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001799788 |
| Ticker | GLSI |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.greenwichlifesciences.com |
| Listed | 2020-09-25 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report